A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 After Single Ascending Doses to Healthy Males
Completed
AstraZeneca
Phase 1
This study will be a randomized, single-blind, placebo-controlled first-in-human study in
healthy male subjects to assess the safety, tolerability and pharmacokinetics of single
ascending doses of AZD9977. In Part B of this study the regional absorption of AZD9977 along
the gastro-intestinal tract will be investigated using the IntelliCap® system in a
non-randomized, open-label, fixed-sequence design. The study will be performed at a single
study centre.
A Study to Assess the Pharmacodynamic Effect of Single Doses of AZD9977 in Healthy Male Subjects
Completed
AstraZeneca
Phase 1
This is a Phase I, Randomized, Single-Blind, Crossover Study to Assess the Pharmacodynamics
of AZD9977 following Single-Dose administration to healthy male subjects
A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects
Withdrawn
AstraZeneca
Phase 1
This is an open-label, randomized, cross over single oral dose study to compare the
pharmacokinetics of different formulations of AZD9977 in Part A and the influence of food in
Part B in healthy male subjects
Multiple-ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Healthy Male Subjects
Completed
Parexel
Phase 1
This is a randomized, single-blind, placebo-controlled study conducted on healthy male
subjects at a single study center to assess the safety, tolerability and the pharmacokinetics
of AZD9977 following multiple-ascending oral doses at steady state
Multiple-ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Healthy Male Subjects
Completed
AstraZeneca
Phase 1
This is a randomized, single-blind, placebo-controlled study conducted on healthy male
subjects at a single study center to assess the safety, tolerability and the pharmacokinetics
of AZD9977 following multiple-ascending oral doses at steady state
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
